NJ-Based ReGen Teams Up With Local Investment Firm

ReGen Biologics, a Franklin Lakes, NJ, developer of collagen scaffold technology, announced Thursday that it has completed a $2.7 million round of private equity funding. Montvale, NJ-based Ivy Capital Partners, which specializes in the musculoskeletal sector, led the placement. ReGen’s scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. ReGen’s first approved product is a meniscus application called CMI, which is currently approved for sale in Europe. The company has submitted a 510(k) for U.S. clearance.

The comments are closed.